Tarsus Pharmaceuticals (TARS) opened 2026 with Q1 revenue of US$162.1 million and a basic EPS loss of US$0.16, alongside a trailing twelve month revenue base of US$535.1 million and a net loss of US$48.3 million. Over recent quarters the company has seen quarterly revenue move from US$66.4 million in Q4 2024 to US$78.3 million in Q1 2025 and then to US$162.1 million in Q1 2026. Basic EPS losses over the same snapshots were US$0.60, US$0.64 and US$0.16 respectively, highlighting a narrative that now focuses on how quickly margins can tighten and losses can be contained.

See our full analysis for Tarsus Pharmaceuticals.

With the headline numbers on the table, the next step is to see how this earnings profile lines up against the widely followed growth, profitability and valuation narratives around Tarsus Pharmaceuticals.

Losses Narrow On Higher Revenue Base

• On a trailing twelve month basis, Tarsus reported US$535.1 million in revenue and a net loss of US$48.3 million, compared with a quarterly loss of US$6.97 million in Q1 2026 on US$162.1 million of revenue.
• Bulls point out that forecasts of 17.6% annual revenue growth and 52.18% annual earnings growth, along with an expectation of profitability within three years, sit alongside this recent pattern of smaller quarterly losses. They see this as early support for a long term margin improvement story.
  • Quarterly net loss has moved from US$25.1 million in Q1 2025 to US$6.97 million in Q1 2026, while revenue over the same snapshots rose from US$78.3 million to US$162.1 million.
  • On a trailing basis, net loss of US$48.3 million compares with US$66.4 million at the end of 2025, which bullish investors weigh against the still unprofitable status flagged in the 23.2% annual loss growth figure over five years.

Bulls who see Q1 as an early proof point for that improvement path can test their view against a detailed narrative in 🐂 Tarsus Pharmaceuticals Bull Case

Valuation Gap Versus DCF Fair Value

• The current share price of US$63.96 sits well below the cited DCF fair value of US$329.96 and under the 94.11 analyst price target, while the P/S ratio of 5.1x is slightly below the 5.2x US Pharmaceuticals industry average and far below the 13.6x peer average.
• Consensus narrative highlights that analysts expect revenue to grow 33% per year and earnings to reach US$265.3 million by 2029. They anchor a 94.11 price target on those assumptions, which some investors compare to the much higher DCF fair value to judge whether the current P/S discount is a reflection of the five year 23.2% annual loss growth or an opportunity if the forecast margin shift to 25% within three years is achieved.
  • The gap between US$63.96 and the analyst target of 94.11 is paired with a trailing twelve month loss of US$48.3 million, so the stock is still priced on expectations of future profitability rather than current earnings.
  • The DCF fair value of US$329.96 is very large relative to both the share price and the analyst target. This can encourage readers to focus closely on whether forecast revenue paths around US$1.1b by 2029 feel realistic given today’s US$535.1 million trailing revenue base.

Five Year Loss Trend Keeps Bears Focused

• Over the past five years, losses have grown at about 23.2% per year, and the latest trailing twelve month basic EPS is a loss of US$1.13 per share, alongside a Q1 2026 basic EPS loss of US$0.16.
• Bears argue that reliance on a single commercial product and continued high spending mean that even with trailing revenue at US$535.1 million, the company remains in a loss making position. They question whether projected revenue growth of 29.8% per year and a move to a 19% margin within three years is enough to offset risks from pricing pressure and competition given the current US$48.3 million trailing loss and the multi year loss growth record.
  • The progression from a Q1 2025 loss of US$25.1 million on US$78.3 million of revenue to a Q1 2026 loss of US$6.97 million on US$162.1 million of revenue offers data points that some see as improvement, but it does not change the fact that profitability is not yet established.
  • The bearish narrative also weighs the five year 23.2% annual loss growth against analyst expectations for US$187.6 million of earnings by 2029, highlighting how much needs to change from the current trailing loss of US$48.3 million for that outcome to be reached.

If you are weighing these risks more heavily, it is worth reading how skeptics frame the downside in the 🐻 Tarsus Pharmaceuticals Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Tarsus Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both bull and bear arguments, consider whether the balance of optimism and concern aligns with your own risk tolerance and time horizon. You may wish to act while the details are fresh in mind by reviewing the 4 key rewards and 1 important warning sign

See What Else Is Out There

Tarsus Pharmaceuticals still carries a trailing twelve month loss of US$48.3 million and a five year record of loss growth, so profitability risk remains front and center.

If that ongoing loss profile feels uncomfortable, you may want to shift some research time toward companies with stronger downside protection by checking out 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.